ParcelShield offers predictive parcel surveillance technology, driven by machine learning algorithms, to protect critical package deliveries primarily for specialty pharmacies, mail order pharmacies, and specialty pharmaceutical distributors in the United States.  The Company’s primary service offerings include (i) predicting potential route disruptions and package distress using predictive analytics, (ii) monitoring shipments in real time through a customer-facing surveillance portal, (iii) intercepting distressed shipments and coordinating successful delivery, and (vi) proactively engaging consumers to manage on-time deliveries.  The Company’s services are enabled by a proprietary data model and analytics platform based on more than 17 years of shipping data that allows ParcelShield to protect high-cost, temperature-sensitive, and life-sustaining pharmaceuticals on behalf of its clients.

Top Down Investment Thesis

Excellere’s investment in ParcelShield is based upon the convergence of several long-term themes in the pharmaceutical supply chain and broader healthcare industries, including (i) expansion of the overall specialty pharmacy pipeline increasing the supply of high-price, patient-specific medications in the marketplace, (ii) growing demand for home delivery of medications and heightened consumer expectations for timely and reliable delivery, and (iii) new and evolving regulatory requirements, such as URAC 4.0, that demand greater visibility of product in the pharmaceutical supply chain.  ParcelShield’s innovative predictive parcel technology platform solves these complex issues and generates a highly compelling financial ROI for its customers of greater than 25x, alongside tangible benefits to patient satisfaction and retention rates.

The parcel shipping market is experiencing substantial growth as the surge in e-commerce is driving increasing consumer expectations for express delivery direct to homes.  Global package shipping volume rose 48% from 2014 to 2016 and is expected to continue to rise more than 20% annually through 2021.  E-commerce has been the biggest contributor to shipping volume trends with consumers spending $517 billion online in 2018 in the US alone, which was up from 15% in 2017.  Healthcare-specific online spending has continued to grow as well with the percentage of online and mail-order drug spend projected to increase from 25% in 2017 to 36% in 2022.  A large portion of this growth will be through online and mail-order pharmacies, which are expected to grow at 10% annually through 2022.  Rising consumer expectations of convenience coupled with increased pricing pressure will drive a greater percentage of prescription drug spending online in the years to come.

Buy and Build

The market for predictive parcel surveillance and engagement services has substantial tailwinds due to declining profitability margins for specialty and mail order pharmacies driving a need for cost mitigation measures, pharmacies’ need to improve the consumer’s overall experience, and tightening regulations in drug distribution channels.  ParcelShield is well positioned to capitalize on these opportunities as a result of its proprietary parcel surveillance technology platform that is unmatched by anything currently in the market.  To the extent you are interested in learning more about ParcelShield, please contact Brad Cornell at , Mike Vieth at , or Chris Flight at .

SePRO Corporation is dedicated to discovering and developing sustainable solutions.  Founded in 1994 and based in Carmel, Indiana, SePRO is a research based specialty chemicals company that provides products and services for plant management, plant protection and specialty agriculture.  SePRO’s products and services are used in multiple end markets including aquatic invasive weed management, algae and water quality, turf and landscaping management, ornamental and greenhouse markets, as well as specialty agriculture.  The company acquires, develops, manufactures, and markets value-added products and is the industry-leading provider of application, lab testing and technical support services.  SePRO has partnered with several of the top agriculture chemical companies to develop chemistries for use in SePRO’s key markets.  Central to its product innovation and technical support services is a 410-acre SePRO Research & Technology Campus (SRTC) in Whitakers, NC.

Top-Down Investment Thesis

SePRO operates in the aquatic invasive weed management, algae and water quality, turf, ornamental, and specialty agriculture markets.  According to a market study, the U.S. aquatic herbicide and algae markets are sized at approximately $155 million and $515 million, respectively, and are expected to grow at 8.0%-9.0% and 4.5%-5.0% annually over the next five years.  Market growth is being driven by rising global temperatures, increasing both nutrient runoff in waterways and the severity of drought and flooding.  These conditions provide favorable environments for aquatic plants, increasing the prevalence of invasive weeds and algae blooms.  Invasive weeds and algae have negative impacts on property values, local economies, recreational activities, fish populations and native ecosystems. Customers, particularly state governments and large waterbody management agencies and companies, place a high level of importance on product performance, technical support and application expertise. SePRO is recognized as the market-leader with these capabilities.  Additionally, growing emphasis is being placed on sustainable solutions and reduced-risk profile technologies.  SePRO leads the industry in research and product innovation, advancing the aquatics industry with new, proprietary, and eco-friendly chemistries, such as ProcellaCOR, that meet these demands.

The U.S. market for cotton herbicides is approximately $265 million, with an estimated $80 million spent on pre-emergent herbicides.  Herbicides are critical to cotton growers’ ability to preserve yield, as invasive weeds such as pigweed can infest growing fields and reduce productivity by approximately 30%.  Given growing herbicide resistance issues, cotton agronomists have recommended the complementary use of pre- and post-emergent herbicides.  SePRO’s new, pre-emergent herbicide product, Brake, has proven to be highly effective and long-lasting with a different mode of action than existing herbicides driving adoption as a rescue tool for farmers facing resistance issues.  In addition, SePRO has several biological products in its development pipeline focused on other the specialty agriculture markets for use in both traditional and organic crops with demonstrated activity against viruses, fungi, mildew, foliar bacteria and/or soil-borne pathogens.

The $860 million U.S. turf and ornamental chemicals market is projected to grow at 1.6% annually, with fungicides and plant growth regulators (“PGRs”) outpacing the market growth at 2.5-3.0% annually.  Increased use of PGRs is being driven by golf course superintendents and landscaping companies seeking to reduce manual labor associating with cutting faster growing grass and hedges.  Increased use of fungicides is being driven by resistance issues to older chemistries as well as the introduction of new products for specialty solutions.  End users of this market typically buy through early order, bundled product programs due to a preference for rebates and desire to simplify purchasing.  SePRO has highly efficacious PGRs and has new fungicides in development to add to its portfolio that will create a more robust bundled offering.

Buy and Build Strategy

SePRO’s success over the years has been based on its product innovation, proprietary technology and unique technical expertise and service capabilities.  As a result, SePRO benefits from exceptional longstanding partnerships with its customers, distributors and suppliers.  SePRO is a highly compelling platform for acquisitions due to its industry-leading capabilities, channel relationships and national reach and reputation.  The Company is pursuing strategic acquisition and partnership opportunities in the specialty chemicals and agribusiness industries, including companies and technologies focused on plant protection/management, turf management, water quality, specialty agriculture as well as other environmental and horticulture markets.  Opportunities could include both traditional and bio-rational solutions, including but not limited to herbicides, fungicides, algaecides, insecticides/pesticides, molluscicides, virucides, biological enzymes, as well as PGRs, soil surfactants and agents, fertilizers and other specialty chemicals.

To the extent you are interesting in learning more about SePRO, please contact Patrick O’Keefe at or Matt Halverson at .

Concord Technologies is a leading SaaS provider of cloud-based document transfer and workflow solutions to more than 1,500 healthcare organizations and companies in other document-intensive industries in which data security and privacy are paramount.  Within the healthcare ecosystem, Concord’s solutions promote data interoperability through the efficient and secure exchange of critical, time-sensitive and private documents between independent organizations, including medical records, prior authorizations and explanations of benefits, among many others.  In addition, Concord’s AI-powered workflow solutions allow organizations to receive, ingest and direct large amounts of inbound unstructured data, while enabling greater efficiency through tools that allow for document recognition, searchability, extraction, archiving and automation.

Top Down Investment Thesis

Concord’s solutions address the pervasive challenge faced by constituents across the healthcare ecosystem in managing the vast amounts of critical data in paper-based, unstructured formats that cannot be easily transmitted, processed or accessed to support patient care.  According to LEK, approximately 64 billion pages of healthcare data was transmitted in 2018, including medical records, patient referrals, diagnostic test results, and prior authorizations, among many others.  Of all healthcare document transfers, approximately 80% were transmitted via fax due to fax’s unique ability to connect all healthcare constituents via a common medium in a HIPAA compliant manner.  As a result, the U.S. market for cloud fax services is estimated to be $750 million and is expected to grow approximately 13% per year as utilization of healthcare services continues to grow and practices replace legacy paper-based fax architecture with SaaS-based cloud fax solutions.

Despite its advantages and ubiquity in healthcare, fax documents contain only unstructured data which lacks a common format or metadata that would allow for easy automation, data capture, and integration into enterprise technology systems, such as EMR platforms.  In fact, Optum estimates that 80% of the health data it receives is in an unstructured format, which must undergo manual review, data abstraction, and management by staff members in order to be converted into a usable, structured data format.  This takes clinical staff away from patient care, increases the incidence of human-introduced errors, and increases the overall cost of healthcare through inefficient and expensive manual handling.  Concord’s NEXTSTEP solution, through its machine learning and native language processing engines, alleviates many common challenges in its ability to automate the recognition, extraction, structuring and integration of data into external systems or route the information to appropriate recipients based on documents received via fax, scanned paper documents and PDF.  Through these automated functions, NEXTSTEP creates significant cost savings, reduces error rates, and makes available vast amounts of previously inaccessible data contained in unstructured form.

Buy and Build

The market for secure document transfer, capture, and workflow automation within healthcare has substantial tailwinds due to the continued push to reduce cost, increase interoperability, and improve patient care.  Concord’s platform is well positioned to continue its organic growth trajectory due to its market-leading cloud fax platform, further enhanced by its proprietary workflow automation and data capture solutions.  To the extent you are interested in learning more about Concord, please contact Ryan Glaws at or Mike Vieth at .

Founded in 1997 and based in Pacheco, CA, Biocare Medical (“Biocare”) is an oncology-focused developer of immunohistochemistry (“IHC”) and molecular reagents, as well as the associated instrumentation.  With a product portfolio of patented and licensed products, Biocare offers a comprehensive suite of reagents, equipment, and lab services to clinical laboratories, research organizations, and pharmaceutical manufacturers.  Serving nearly 2,000 customers worldwide with a catalogue of over 2,000 unique product SKUs, customers rely on Biocare’s product quality and consistency for their research and clinical needs.

Top Down Investment Thesis

Excellere’s investment in Biocare is a result of the firm’s disciplined top down investment strategy, driven by several factors including i) a compelling value proposition to medical and research professionals who can better identify cancer with enhanced specificity, ii) attractive industry growth driven by increasing cancer incidence rates and expanding testing and research needs, iii) IHC’s position as the most widely used platform in histopathology and standard of care for cancer diagnoses, and iv) the buy-and-build opportunity within a highly fragmented industry sector that Excellere pursued for approximately five years and established a list of over 100 acquisition candidates and industry relationships.

The reagents industry is large, global and fast growing with several drivers providing attractive tailwinds.  Biocare’s primary end-market is cancer research and detection, one of the most attractive sub-segments within the broader life sciences tools sector.  According to LEK, worldwide cancer incidence is expected to grow 2.4% per annum to nearly 17.1 million new cancer diagnoses in 2020.  Increases in the total number of new cancer diagnoses are driving an expanding number of U.S. biopsy procedures and ultimately growing consumption of reagents.  The worldwide IHC and molecular diagnostics market is expected to grow to $2.4 billion by 2021, reflective of approximately 5% annual growth driven by cancer incidence rate growth, development of new biomarkers, and pricing increase within the currently primary technology for the cancer diagnostic value chain.

Buy and Build Strategy

Consumable life science and diagnostic tools remains a highly fragmented industry with a multitude of organic and acquisition growth opportunities.  Since inception, Biocare has remained focused on providing world class immunohistochemistry and molecular products solely focused on the attractive, growing oncology market with an emphasis on cancer research, diagnostics, and monitoring.  Biocare’s significant historical investments in its research and development capabilities, manufacturing footprint, strong executive team and a global sales force provides the scale required to serve a substantial worldwide customer base.

To the extent you are interested in learning more about Biocare, please contact Ryan Glaws at , Justin Unertl at , or Nick Coleman at to discuss the life science tools sector further.

Founded in 1980 and based in Hamilton, NJ, Medlogix is a premier provider of medical claims management solutions to leading auto insurance carriers, administrators for workers’ compensation and group health insurers. Leveraging its proprietary technology platform and deep clinical expertise, Medlogix offers a full suite of medical claims management services including pre-certification, independent medical exams, medical director review, medical bill and code review, and bill negotiation support as well as operates a proprietary PPO network in the northeastern United States.

Top Down Investment Thesis

Excellere’s investment in Medlogix is a result of the firm’s disciplined top down investment strategy, driven by several factors including i) rising medical costs driving an increase in auto and workers’ compensation claim severity, ii) persistence of improper billing and fraudulent claims within the auto and workers’ compensation industries, iii) carrier’s enhanced focus on effective loss prevention and cost containment solutions, and iv) growing utilization of outsourced service providers that improve efficiency and offer a quantifiable ROI.

According to the Insurance Research Council and National Insurance Crime Bureau, annual costs related to improper billing or fraudulent claims in the auto insurance and workers’ compensation industries are estimated to total up to $7.7 and $7.2 billion, respectively.  Despite a decline in claim frequency, since 2005 rising medical costs have driven an increase in claim severity (per claim cost) of 35.5% for bodily injury liability claims and 40.7% for workers’ compensation claims. Persistent claim fraud, rising medical costs and growth in claim severity are propelling the need for greater, more robust claims management and cost control measures among insurers and corporations; outsourced providers of medical claims management services offer an essential, highly effective loss containment solution. Medlogix’s medical claims management solutions and proprietary PPO network help carriers i) identify areas for cost savings tied to improper billing and limit leakage due to payment of fraudulent claims, ii) reduce administrative expenses associated with claims adjudication, and iii) lower medical treatment costs. Combined, the Company’s services deliver a more efficient and disciplined claims process, resulting in greater productivity and reduced severity for its customers.

Buy and Build Strategy

Medical claims management is a highly fragmented industry, which combined with continued trends in the outsourcing of non-core service functions by carriers, creates an attractive sector to employ a buy-and-build strategy. It is estimated that there are currently more than 500 outsourced medical claim service providers in the United States, the vast majority of which are regionally focused and family owned. Medlogix is focused on partnering with organizations known for service quality and excellence in complementary business lines and operating in favorable geographies.

To the extent you are interested in learning more about Medlogix, please contact Matt Hicks at , Ross Gundry at , or Nick Coleman at to discuss the medical claims management services sector further.

LucidHealth is a leading provider of professional radiology services to hospitals, clinics and outpatient imaging centers, completing over 1.7 million interpretations per year.  Powered by the belief that all patients should have access to the highest quality of subspecialized imaging care, regardless of facility size or location, LucidHealth leverages its internally developed, industry-leading workflow technology and clinical processes to provide the highest-quality, subspecialized care for patients and referring physicians.  Founded in 1980 and based in Ohio, LucidHealth is a top ten provider of radiology services in the United States.

Top Down Investment Thesis

According to WallStreet Research, United States commercial healthcare spending on the radiology industry is over $200 billion per annum and is expected to grow at a 10% CAGR from 2015-2020, driven by constantly evolving imaging technologies and the overall expansion of healthcare.  Imaging and radiology services are one of the largest spend categories at hospitals, representing nearly 10% of total U.S. commercial healthcare spending each year.  Hospitals are continuing to outsource highly subspecialized services such as radiology due to operational challenges associated with keeping them in-house.  In addition to challenges related to recruiting, retention, and billing, hospitals often are forced to pay for full-time employees regardless of whether there is enough volume to justify an on-staff physician.  Outsourced models allow hospitals to benefit from high-quality subspecialty providers, while enjoying the flexibility of only paying for services that are needed.

With the implementation of PQRS and transition to MACRA and other reforms, payers have become increasingly focused on monitoring quality outcomes to justify reimbursement, and LucidHealth is well positioned to benefit from these changes due to its investments in technology and infrastructure.  In turn, this is propelling growth in imaging services as a way to increase efficiency and drive elevated clinical outcomes.  Radiology is a leading driver of key hospital metrics such as patient safety, emergency department throughput, length of stay, referral patterns and overall patient experience.

Excellere’s investment in LucidHealth is a result of the firm’s disciplined top down investment strategy, driven by several factors including i) expectations for the continued outsourcing of radiology services, ii) an increased aversion to malpractice liability from misdiagnosis, iii) relative stability in radiology reimbursement rates for professional services, and iv) increased focus on quality outcomes within the medical community.

Buy and Build Strategy

Radiology is one of the most fragmented medical subspecialties, which combined with positive outsourcing trends, makes it an attractive subsector to employ a buy-and-build strategy.  It is estimated that there are currently more than 3,000 radiology groups in the United States, with only the top 15 in the country having more than 65 radiologists in their practice.  LucidHealth is focused on partnering within radiology service providers with a culture of compliance, best-in-class patient outcomes, and a patient-first approach clinically and operationally.

To the extent you are interested in learning more about LucidHealth, please contact Patrick O’Keefe at , Justin Unertl at , or Nick Coleman at to discuss the radiology services sector further.

G2 Integrated Solutions is a provider of asset integrity solutions to midstream and downstream energy companies, offering a suite of services designed to help clients manage risk within their existing transmission and distribution networks, demonstrate regulatory compliance, and extend the useful lives of their infrastructure assets. The Company leverages customers’ internal data and records, its proprietary tools and methodologies, and a deep pool of highly trained professionals to solve complex operating problems for an extensive client base that includes a number of high profile North American pipeline operators and natural gas utilities.

Top Down Investment Thesis

Given the dramatic increase in activity in the domestic energy market, aging midstream and downstream infrastructure, and an increasingly stringent regulatory environment surrounding these assets, Excellere believes that there is an opportunity to establish a vertically integrated integrity management services provider that operates through a national footprint and broad suite of capabilities. Excellere’s investment into G2 Integrated Solutions is driven by a number of dynamics, including (i) the opportunity to deliver G2’s broad suite of advanced technical solutions to a diverse set of clients that are focused upon risk management solutions and regulatory compliance support, and (ii) attractive end market fundamentals, whereby new project build-out is resulting in an expanded installed base for service and an aging infrastructure is positioning high-quality integrity management services providers for future growth.

Increasing global demand, advancements in horizontal drilling and hydraulic fracturing technologies and new discoveries of economically viable basins have contributed to the continued emphasis on unconventional oil and gas production. In order to support this increased activity, energy companies are required to build infrastructure to integrate new producing regions into existing midstream and downstream networks, maintain and support aging infrastructure given increased throughput, and engineer complex solutions such as converting gas pipelines to liquids in order to respond to market conditions. Furthermore, given the increase in energy activity and the number of high profile catastrophic incidents, an increasingly stringent regulatory environment has evolved, which is driving higher compliance standards. As a result, the North American natural gas industry is currently projected to spend an estimated $20.0 billion annually through 2035 to build new infrastructure and maintain existing assets, resulting in substantial future opportunities for integrity management service providers with advanced technical capabilities and broad service offerings.

Buy and Build Strategy

The North American asset integrity market is highly fragmented with numerous independent product and service providers. As such, G2 Integrated Solutions is well-positioned to add complementary capabilities and extend its geographic reach via acquisitions. The fragmentation in this market, coupled with the increased importance of domestically produced oil and natural gas to the North American energy supply, has created an opportunity to build a full-scale integrity management solutions provider to midstream and downstream energy companies. Specific areas of interest within the systems integrity management industry include: (i) complementary high-end infrastructure engineering services, (ii) GIS products and services, (iii) data analytics and management, and (iv) safety services.

To the extent you are interested in learning more about G2 Integrated Solutions or the integrity management industry, please contact David Kessenich at or Brad Cornell at .

Advanced Infusion Solutions (“AIS”) is a compliance focused provider of patient-specific medications for chronic pain patients with intrathecal pumps, as well as for patients requiring other chronic therapies such as immune globulin. Intrathecal drug delivery is a method of providing customized medications directly to a patient’s spinal cord through an implanted pain pump that is surgically placed under the skin of a patient’s abdomen. The pump is programmable to allow for the slow release of patient-specific medication over a period of time through a catheter to a targeted area around the spinal cord and is refilled periodically. Founded in 1998, AIS operates is headquartered in Dallas, Tx and provides services in all 50 states with additional operations in Ridgeland, MS, Clinton, MS, Valdosta, GA and Birmingham, AL.

Top Down Investment Thesis

Excellere’s investment in AIS is based upon (i) the non-discretionary need for intrathecal drug delivery for patients with chronic pain conditions that cannot be improved from further surgeries or oral pain medications, (ii) the highly recurring revenue model of intrathecal pain management, as the estimated 250,000 patients using this treatment receive 4 to 6 pain pump refills annually, and (iii) the highly-fragmented nature of the industry.

The U.S. chronic pain industry, at over $100 billion in annual spending, is characterized by numerous constituents trying to serve the 100+ million Americans suffering from chronic pain linked to diseases and syndromes such as obesity, cancer, diabetes, arthritis, HIV-AIDS, failed surgeries, cerebral palsy, multiple sclerosis and countless other conditions. The industry is expected to continue growing due to (i) a rapidly growing geriatric population – “baby boomers” currently account for 30%+ of the U.S. population, (ii) continued and growing U.S. obesity, which contributes to chronic pain as body structures support heavier weights over time and wear down, (iii) increasing recognition of the therapeutic benefits of effective pain management (specifically, versusoral pain medications) and (iv) expected growth in surgical procedures (29% from 2010 to 2020).

Buy and Build Strategy

The intrathecal pain pump market is composed of approximately 250,000 patients, and is expanding due to the increase in chronic pain patients as well as the recognition of intrathecal pumps as a safe and cost effective treatment methodology for patients that have exhausted other forms of therapy (e.g. continual oral medications and multiple surgeries). AIS’s platform is well positioned to grow both organically and through selective acquisitions due to its (i) compliance-centric model (including USP 797), (ii) growing and recurring patient base, (iii) diversified referral network and (iv) proven growth profile.

To the extent you are interested in learning more about AIS, please contact Ryan Glaws at or Matt Halverson at .